Live search
TopFind is fetching the latest matches for your search.
We reviewed 32 live results for adalimumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Biologic and Medicine.
Source: Bumrungrad International Hospital
Description
A biologic DMARD and TNF inhibitor used for patients with moderate to severe rheumatoid arthritis. Available as sterile solutions for injection (40 mg or 20 mg), it is often reserved for those who do not respond to conventional treatments.
Best for
advanced RA treatment, TNF inhibitor therapy, biologic DMARD access and patients failing conventional therapy
Rating
Source: Sandoz
Description
Hyrimoz is an FDA-approved adalimumab biosimilar and TNF blocker used as a subcutaneous injection to treat inflammatory diseases. It is commonly prescribed for patients with rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a biologic therapy, it helps reduce inflammation and manage symptoms by targeting tumor necrosis factor (TNF) proteins in the body.
Best for
rheumatoid arthritis patients, Crohn's disease therapy, plaque psoriasis treatment, chronic inflammation management and biologic therapy users
Rating
Source: Fresenius Kabi
Description
Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira.
Best for
rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy
Rating
| Compare | Adalimumab | Hyrimoz (adalimumab-adaz) | Idacio (adalimumab) |
|---|---|---|---|
| Source | Bumrungrad International Hospital | Sandoz | Fresenius Kabi |
| Description | A biologic DMARD and TNF inhibitor used for patients with moderate to severe rheumatoid arthritis. Available as sterile solutions for injection (40 mg or 20 mg), it is often reserved for those who do not respond to conventional treatments. | Hyrimoz is an FDA-approved adalimumab biosimilar and TNF blocker used as a subcutaneous injection to treat inflammatory diseases. It is commonly prescribed for patients with rheumatoid arthritis, plaque psoriasis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis. As a biologic therapy, it helps reduce inflammation and manage symptoms by targeting tumor necrosis factor (TNF) proteins in the body. | Idacio is a biosimilar biologic medication containing adalimumab, a TNF-alpha inhibitor used to treat a wide range of inflammatory conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. The medication is typically provided as a 40 mg/0.8 mL solution for subcutaneous injection, available in formats such as a single-dose pre-filled pen (autoinjector), a pre-filled syringe, or a single-dose vial for pediatric or specific dosing needs. As a biosimilar, it offers a clinically equivalent and often more accessible alternative to the reference product Humira. |
| Best for | advanced RA treatment, TNF inhibitor therapy, biologic DMARD access and patients failing conventional therapy | rheumatoid arthritis patients, Crohn's disease therapy, plaque psoriasis treatment, chronic inflammation management and biologic therapy users | rheumatoid arthritis treatment, psoriasis management, Crohn’s disease patients, biosimilar medication seekers and subcutaneous injection therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Adalimumab from Bumrungrad International Hospital."
I picked this because A highly effective biologic option for advanced RA management available at premier private hospitals in Thailand.